News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
402,023 Results
Type
Article (32405)
Company Profile (60)
Press Release (369558)
Section
Business (114084)
Career Advice (1344)
Deals (24225)
Drug Delivery (106)
Drug Development (60191)
Employer Resources (107)
FDA (10104)
Job Trends (9197)
News (213660)
Policy (25680)
Tag
2024 BioCapital Digital (1)
2024 BioForest Digital (1)
2024 BioMidwest Digital (1)
2024 Bio NC Digital (1)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (4)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (1)
2024 Genetown Standard (6)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (1)
2024 Pharm Country Standard (2)
2025 Lone Star Bio Digital (1)
2026 BioCapital Standard (1)
2026 Pharm Country Premier (1)
Academia (1846)
Accelerated approval (3)
Adcomms (22)
Allergies (65)
Alliances (42474)
ALS (60)
Alzheimer's disease (1103)
Antibody-drug conjugate (ADC) (93)
Approvals (10106)
Artificial intelligence (151)
Autoimmune disease (16)
Automation (6)
Bankruptcy (239)
Best Places to Work (7744)
BIOSECURE Act (16)
Biosimilars (80)
Biotechnology (43)
Bladder cancer (46)
Brain cancer (27)
Breast cancer (176)
Cancer (1514)
Cardiovascular disease (132)
Career advice (1126)
Career pathing (19)
CAR-T (104)
Cell therapy (288)
Cervical cancer (16)
Clinical research (48507)
Collaboration (649)
Compensation (382)
Complete response letters (20)
COVID-19 (2479)
CRISPR (30)
C-suite (108)
Cystic fibrosis (57)
Data (1450)
Decentralized trials (1)
Denatured (9)
Depression (35)
Diabetes (222)
Diagnostics (3621)
Digital health (10)
Diversity (4)
Diversity, equity & inclusion (34)
Drug discovery (83)
Drug pricing (102)
Drug shortages (30)
Duchenne muscular dystrophy (77)
Earnings (40534)
Editorial (36)
Employer branding (13)
Employer resources (96)
Events (46222)
Executive appointments (303)
FDA (10917)
Featured Employer (18)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (5)
Funding (475)
Gene editing (72)
Generative AI (12)
Gene therapy (224)
GLP-1 (748)
Government (4096)
Grass and pollen (4)
Guidances (34)
Healthcare (11522)
Huntington's disease (18)
IgA nephropathy (21)
Immunology and inflammation (81)
Indications (21)
Infectious disease (2610)
Inflammatory bowel disease (76)
Inflation Reduction Act (8)
Influenza (49)
Intellectual property (67)
Interviews (232)
IPO (10510)
IRA (40)
Job creations (1801)
Job search strategy (970)
Kidney cancer (7)
Labor market (15)
Layoffs (280)
Leadership (8)
Legal (7071)
Liver cancer (49)
Lung cancer (220)
Lymphoma (102)
Machine learning (4)
Management (33)
Manufacturing (221)
MASH (54)
Medical device (6069)
Medtech (6070)
Mergers & acquisitions (14091)
Metabolic disorders (623)
Multiple sclerosis (52)
NASH (20)
Neurodegenerative disease (67)
Neuropsychiatric disorders (22)
Neuroscience (1476)
NextGen: Class of 2025 (3718)
Non-profit (2789)
Northern California (1567)
Now hiring (19)
Obesity (361)
Opinion (193)
Ovarian cancer (53)
Pain (49)
Pancreatic cancer (63)
Parkinson's disease (109)
Partnered (12)
Patents (149)
Patient recruitment (59)
Peanut (38)
People (25443)
Pharmaceutical (19)
Pharmacy benefit managers (12)
Phase I (14661)
Phase II (21038)
Phase III (17091)
Pipeline (847)
Podcasts (57)
Policy (113)
Postmarket research (1879)
Preclinical (6049)
Press Release (29)
Prostate cancer (74)
Psychedelics (30)
Radiopharmaceuticals (205)
Rare diseases (263)
Real estate (2668)
Recruiting (45)
Regulatory (16234)
Reports (23)
Research institute (1612)
Resumes & cover letters (199)
Rett syndrome (3)
RNA editing (3)
RSV (44)
Schizophrenia (60)
Series A (85)
Series B (44)
Service/supplier (4)
Sickle cell disease (41)
Southern California (1277)
Special edition (6)
Spinal muscular atrophy (137)
Sponsored (18)
Startups (1935)
State (1)
Stomach cancer (11)
Supply chain (52)
Tariffs (10)
The Weekly (46)
United States (12766)
Vaccines (689)
Venture capitalists (28)
Webinars (5)
Weight loss (284)
Women's health (13)
Worklife (10)
Date
Last 7 days (434)
Last 30 days (1708)
Last 365 days (21626)
2025 (5443)
2024 (22696)
2023 (25524)
2022 (33719)
2021 (36225)
2020 (34377)
2019 (28234)
2018 (21497)
2017 (20535)
2016 (18953)
2015 (21783)
2014 (16212)
2013 (13122)
2012 (13933)
2011 (14671)
2010 (13292)
Location
Africa (580)
Alabama (29)
Alaska (5)
Arizona (87)
Arkansas (6)
Asia (26123)
Australia (4751)
California (3406)
Canada (1160)
China (348)
Colorado (146)
Connecticut (156)
Delaware (93)
Europe (63555)
Florida (513)
Georgia (123)
Hawaii (1)
Idaho (28)
Illinois (277)
India (21)
Indiana (186)
Iowa (7)
Japan (111)
Kansas (62)
Kentucky (15)
Louisiana (9)
Maine (28)
Maryland (621)
Massachusetts (2462)
Michigan (110)
Minnesota (139)
Mississippi (1)
Missouri (48)
Montana (20)
Nebraska (14)
Nevada (34)
New Hampshire (22)
New Jersey (1089)
New Mexico (15)
New York (1026)
North Carolina (493)
North Dakota (4)
Northern California (1567)
Ohio (111)
Oklahoma (6)
Oregon (12)
Pennsylvania (753)
Puerto Rico (4)
Rhode Island (14)
South America (806)
South Carolina (10)
South Dakota (1)
Southern California (1277)
Tennessee (52)
Texas (436)
Utah (76)
Virginia (86)
Washington D.C. (36)
Washington State (289)
West Virginia (2)
Wisconsin (28)
402,023 Results for "novo nordisk ferment ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Podcasts
COVID Reflections, Novo’s Next-Gen Weight Loss Struggles, Another Depression Miss, More
BioSpace
remembers COVID-19 five years after the pandemic was declared, Novo Nordisk’s CagriSema again misses expectations as the company joins a lawsuit filed by drug compounders against the FDA, Viking secures ample supply of its investigational obesity medication, J&J strikes out in depression, and Makary and Bhattacharya near confirmation.
March 12, 2025
·
1 min read
·
Heather McKenzie
Podcast
Trump’s Pharma Tariffs, Monarez for CDC, Novo’s New Obesity Play, More
President Donald Trump continues to warn of tariffs on the pharmaceutical industry; Susan Monarez replaces Dave Weldon as CDC director nominee; Novo Nordisk joins the triple-G race; Alnylam wins approval for Amvuttra in ATTR-CM; and Cassava Sciences ends development of simufilam in Alzheimer’s.
March 26, 2025
·
1 min read
·
Heather McKenzie
Press Releases
Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851
March 31, 2025
·
5 min read
Press Releases
Novo Nordisk announces changes in Executive Management
April 3, 2025
·
2 min read
Rare diseases
Novo’s Bispecific for Hemophilia Aces Phase III Pediatric Trial
Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III FRONTIER3 trial. The company plans to file for approval this year, hoping to compete in the hemophilia A space with Roche’s
blockbuster
Hemlibra.
February 7, 2025
·
2 min read
·
Dan Samorodnitsky
Obesity
‘There’s Only One Semaglutide’: Novo CEO Admits Compounders Are Hurting Weight Loss Business
Compounded versions could make up as much as 40% of the semaglutide market, said Novo Nordisk CEO Lars Fruergaard Jorgensen on Thursday, but the company hopes to win patients over.
March 28, 2025
·
1 min read
·
Annalee Armstrong
Legal
Novo Enters the Ring in Legal Fight Against GLP-1 Compounders as Lilly Notches Victory
Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision to declare the Wegovy shortage over. Eli Lilly did the same in a parallel case over Zepbound’s removal from the FDA shortage list and this week a judge denied the compounders’ injunction.
March 6, 2025
·
3 min read
·
Kate Goodwin
Legal
Novo Seeks $830M in Fraud Case Against Singaporean Biotech Over Kidney Drug
Back in 2023, Novo Nordisk committed up to $1.3 billion for a hypertension and kidney disease drug from KBP Biosciences. Now, the pharma giant claims to have been misled by the biotech’s founder—and a judge seems to agree.
February 18, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S
February 27, 2025
·
1 min read
Podcast
FDA on Fire, Novo’s Mixed Bag of Semaglutide Cardio Data, Kisunla’s EU Miss, More
Biopharma leaders react to the forced resignation of CBER Head Peter Marks as RFK Jr.’s promised job cuts begin at the FDA; Novo Nordisk presents mixed results from oral semaglutide in cardiovascular disease; the EU’s Committee for Medicinal Products for Human Use declines to recommend Eli Lilly’s Alzheimer’s drug; and pharma R&D returns grew in 2024.
April 2, 2025
·
1 min read
·
Heather McKenzie
1 of 40,203
Next